COH-18157-HL: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Protocol No
COH-18157-HL
Principal Investigator
Mehdi Hamadani
Phase
II
Summary
Brentuximab is an antibody attached to a chemotherapeutic drug targeted against Hodgkin lymphoma cells. Nivolumab is an antibody that enhances the immune system to better attack Hodgkin lymphoma cells. It has shown that both drugs induce high response rates in relapsed or refractory Hodgkin lymphoma.
Description
PET CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab and RT Free Management in cHL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL